scholarly journals Stem cell therapies for chronic obstructive pulmonary disease: current status of pre-clinical studies and clinical trials

2018 ◽  
Vol 10 (2) ◽  
pp. 1084-1098 ◽  
Author(s):  
Zhongwei Sun ◽  
Feng Li ◽  
Xin Zhou ◽  
Kian Fan Chung ◽  
Wen Wang ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Clinical Trials ◽  
Stem Cell ◽  
Pulmonary Disease ◽  
Clinical Studies ◽  
Current Status ◽  
Chronic Obstructive ◽  
Stem Cell Therapies ◽  
Obstructive Pulmonary Disease ◽  
Cell Therapies

Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD)

2019 ◽  
Vol 26 (39) ◽  
pp. 7048-7058 ◽  
Author(s):  
Patrizia Russo ◽  
Giulia Prinzi ◽  
Palma Lamonaca ◽  
Vittorio Cardaci ◽  
Massimo Fini
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Clinical Studies ◽  
Risk Prevention ◽  
Chronic Obstructive ◽  
Low Molecular Weight ◽  
Important Class ◽  
Cvd Risk ◽  
Obstructive Pulmonary Disease ◽  
Convincing Data

Background: Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases (CV) Often Coexist. COPD and CVD are complex diseases characterized by a strict interaction between environment and genetic. The mechanisms linking these two diseases are complex, multifactorial and not entirely understood, influencing the therapeutic approach. COPD is characterized by several comorbidities, it hypothesized the treatment of cardiovascular co-morbidities that may reduce morbidity and mortality. Flavonoids are an important class of plant low molecular weight Secondary Metabolites (SMs). Convincing data from laboratory, epidemiological, and human clinical studies point the important effects on CVD risk prevention. Objective: This review aims to provide up-to-date information on the ability of Flavonoids to reduce the CVD risk. Conclusion: Current studies support the potential of Flavonoids to prevent the risk of CVD. Well-designed clinical studies are suggested to evaluate advantages and limits of Flavonoids for managing CVD comorbidity in COPD.

Indacaterol in the Treatment of Chronic Obstructive Pulmonary Disease: From Clinical Trials to Daily Practice

2014 ◽  
Vol 9 (2) ◽  
pp. 96-101
Author(s):  
Cristoforo Incorvaia ◽  
Erminia Ridolo ◽  
Edoardo Riario-Sforza ◽  
Marcello Montagni ◽  
Gian Riario-Sforza
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Clinical Trials ◽  
Pulmonary Disease ◽  
Daily Practice ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD)

2020 ◽  
Vol 29 (7) ◽  
pp. 723-738
Author(s):  
Luigino Calzetta ◽  
Beatrice Ludovica Ritondo ◽  
Maria Gabriella Matera ◽  
Gabriella Pezzuto ◽  
Mario Cazzola ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Obstructive Pulmonary Disease ◽  
Clinical Trials ◽  
Phase I ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Phase I And Ii
Sign in / Sign up

Export Citation Format

Share Document